Jessica Tao

Assistant Professor

20132019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2013 2019

2019

Demonstrating the impact of POLST forms on hospital care requires information not contained in state registries

Turnbull, A., Ning, X., Rao, A., Tao, J. & Needham, D., Jun 1 2019, In : PloS one. 14, 6, e0217113.

Research output: Contribution to journalArticle

Open Access
physicians
Registries
Physicians
Resuscitation Orders
Proxy

First-in-human phase i study of the activin a inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors

Tao, J. J., Cangemi, N. A., Makker, V., Cadoo, K. A., Liu, J. F., Rasco, D. W., Navarro, W. H., Haqq, C. M. & Hyman, D. M., Sep 15 2019, In : Clinical Cancer Research. 25, 18, p. 5458-5465 8 p.

Research output: Contribution to journalArticle

Granulosa Cell Tumor
Activins
Ovarian Neoplasms
Growth Differentiation Factor 2
Neoplasms

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., Timaul, N. M., Mcgriskin, R., Outmezguine, N. A., Zhao, H. Y., Chang, Q., Qeriqi, B., Barbacid, M., de Stanchina, E., Hyman, D. M., Bollag, G. & 1 others, Rosen, N., Feb 1 2019, In : Nature medicine. 25, 2, p. 284-291 8 p.

Research output: Contribution to journalLetter

Dimers
Monomers
Drug Resistance
Neoplasms
Protein Isoforms
2018

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology

Tao, J., Schram, A. M. & Hyman, D. M., Jan 29 2018, In : Annual review of medicine. 69, p. 319-331 13 p.

Research output: Contribution to journalArticle

Oncology
Tumors
Genes
Clinical Trials
Genome

Learning all that we can from MyPathway

Tao, J., Schram, A. M., Harding, J. J., Drilon, A. & Hyman, D. M., Aug 10 2018, In : Journal of Clinical Oncology. 36, 23, p. 2450-2451 2 p.

Research output: Contribution to journalLetter

Learning
2016

Snowflakes in August: Leptospirosis Hemorrhagic Pneumonitis

Sathiyakumar, V., Shah, N. P., Niranjan-Azadi, A., Tao, J., Tsao, A., Martin, I. W., Brotman, D. & Antar, A., 2016, (Accepted/In press) In : American Journal of Medicine.

Research output: Contribution to journalArticle

Leptospirosis
Pneumonia
2015

Long term side effects of adjuvant chemotherapy in patients with early breast cancer

Tao, J., Visvanathan, K. & Wolff, A. C., Nov 1 2015, In : Breast. 24, p. S149-S153

Research output: Contribution to journalArticle

Adjuvant Chemotherapy
Breast Neoplasms
Therapeutics
Disease-Free Survival
Quality of Life

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., Minuesa, G., Morse, N., Rodón, J., Ibrahim, Y., Cortes, J., Perez-Garcia, J., Galvan, P., Grueso, J., Guzman, M., Katzenellenbogen, J. A. & 8 others, Kharas, M., Lewis, J. S., Dickler, M., Serra, V., Rosen, N., Chandarlapaty, S., Scaltriti, M. & Baselga, J., Apr 15 2015, In : Science translational medicine. 7, 283, 283ra51.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
Estrogen Receptors
Hormones
Breast Neoplasms
Neoplasms
2014

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer

Tao, J., Castel, P., Radosevic-Robin, N., Elkabets, M., Auricchio, N., Aceto, N., Weitsman, G., Barber, P., Vojnovic, B., Ellis, H., Morse, N., Viola-Villegas, N. T., Bosch, A., Juric, D., Hazra, S., Singh, S., Kim, P., Bergamaschi, A., Maheswaran, S., Ng, T. & 6 others, Penault-Llorca, F., Lewis, J. S., Carey, L. A., Perou, C. M., Baselga, J. & Scaltriti, M., Mar 25 2014, In : Science signaling. 7, 318, ra29.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
Triple Negative Breast Neoplasms
Epidermal Growth Factor Receptor
Phosphorylation
Tumors
2013

MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., Serra, V., Rodrik-Outmezguine, V., Hazra, S., Singh, S., Kim, P., Quadt, C., Liu, M., Huang, A., Rosen, N., Engelman, J. A. & 2 others, Scaltriti, M. & Baselga, J., Jul 31 2013, In : Science translational medicine. 5, 196, 196ra99.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
Breast Neoplasms
Neoplasms
Neuregulin-1
Cell Line

PI3K pathway inhibitors: Better not left alone

Markman, B., Tao, J. & Scaltriti, M., Jan 1 2013, In : Current Pharmaceutical Design. 19, 5, p. 895-906 12 p.

Research output: Contribution to journalReview article

Phosphatidylinositol 3-Kinases
Neoplasms
Genetic Phenomena
Drug Combinations
Catalytic Domain